~~<i id='D606294396'><strike id='D606294396'><tt id='D606294396'><pre id='D606294396'></pre></tt></strike></i>~~

Home» leisure time» entertainment

entertainment

author：Wikipedia 2025-09-30 05:18:12 Page View：529

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA greenlights medical device to combat bladder issues
Next article： Virginia high school admissions case could be legal follow

explore

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

Doctor appointment wait times are getting worse

SpencerPlatt/GettyImagesIn2004,thephysiciansearchfirmMerrittHawkinsfirstissuedtheirSurveyofPhysician

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

FILE-Abortion-rightsprotestersfillIndianaStatehousecorridorsandcheeroutsidelegislativechambers,Frida

Meta looks to target Twitter with a rival app called Threads

Theannouncementofthesocialmediaapp'Threads'isdisplayedinApple'sUSAppStoreseenonthescreenofasmartphon

WSS

entertainment

entertainment

focus

explore

Meta looks to target Twitter with a rival app called Threads